neuroClues represents a significant advancement in the field of neurologic care, leveraging AI-powered eye-tracking technology to provide practitioners with a non-invasive, quick, and robust method for quantifying clinical examinations. This innovative tool is the culmination of years of research, aiming to offer a better aid in diagnosis through its sensitivity and specificity for ruling out differential diagnoses. Additionally, neuroClues facilitates a more objective follow-up of patients by measuring the evolution of diseases and the efficacy of treatments with high precision.
The technology behind neuroClues is designed to be intuitive, making it an invaluable research tool with high spatial and temporal resolution. It is based on the principle that eye movements can serve as biomarkers for neurological diseases, offering insights that are not easily obtainable through traditional methods. For instance, a 5-minute examination of eye movements can provide more information than a kilometer walk, thanks to the ability to perform three saccades per second, resulting in close to 1000 measurements.
Moreover, neuroClues has the potential to predict disease evolution up to five years in advance, as demonstrated by research linking eye-tracking with disorders. This capability is supported by over 80,000 scientific papers, underscoring the significance of eye movements in understanding and diagnosing neurological conditions.
Currently, neuroClues products are in the research and development phase, with their availability contingent upon compliance with all relevant regulatory requirements. This includes obtaining necessary clearances and approvals from appropriate authorities. The ambition of neuroClues is to revolutionize neurologic care by providing practitioners with a tool that not only enhances diagnostic accuracy but also offers a new level of insight into the progression of neurological diseases.
